mp.weixin.qq.com· 康方医学·· 2026-09-14PickScore61
Ivonescimab Beats Pembrolizumab on Overall Survival in Front-line PD-L1-positive NSCLC in HARMONi-2
依沃西对比帕博利珠单抗一线治疗PD-L1阳性NSCLC（HARMONi-2研究）OS统计学显著阳性结果在WCLC 2026重磅发布
In brief
Ivonescimab beat pembrolizumab as first-line treatment for PD-L1-positive locally advanced or metastatic NSCLC on overall survival in the registrational HARMONi-2 (AK112-303) trial, with the result reaching statistical significance. The randomised, double-blind, multicentre study was presented as a late-breaking oral at WCLC and included in the official press programme. The finding positions ivonescimab, from Akeso, as a competitor to pembrolizumab in this setting.
Why it matters
Statistically significant overall survival win over pembrolizumab in front-line PD-L1-positive NSCLC changes the first-line option.
Source: mp.weixin.qq.com · mp.weixin.qq.com